Cogent Biosciences (COGT) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free COGT Stock Alerts $7.44 -0.03 (-0.40%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 12:17 AM | investing.comCogent Biosciences Inc (COGT)May 16 at 1:46 AM | americanbankingnews.comCogent Biosciences, Inc. Expected to Post Q2 2024 Earnings of ($0.60) Per Share (NASDAQ:COGT)May 15, 2024 | marketbeat.comQ2 2024 Earnings Forecast for Cogent Biosciences, Inc. Issued By HC Wainwright (NASDAQ:COGT)Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Analysts at HC Wainwright lowered their Q2 2024 earnings per share (EPS) estimates for shares of Cogent Biosciences in a note issued to investors on Monday, May 13th. HC Wainwright analyst R. Burns now anticipates that the technology companyMay 15, 2024 | americanbankingnews.comCogent Biosciences (NASDAQ:COGT) Earns Buy Rating from HC WainwrightMay 13, 2024 | finance.yahoo.comWe Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business GrowthMay 13, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $19.00 price target on shares of Cogent Biosciences in a research report on Monday.May 12, 2024 | americanbankingnews.comCogent Biosciences (NASDAQ:COGT) Stock Rating Reaffirmed by Needham & Company LLCMay 12, 2024 | americanbankingnews.comContrasting Cogent Biosciences (NASDAQ:COGT) and TransCode Therapeutics (NASDAQ:RNAZ)May 11, 2024 | americanbankingnews.comWedbush Weighs in on Cogent Biosciences, Inc.'s Q2 2024 Earnings (NASDAQ:COGT)May 11, 2024 | americanbankingnews.comCogent Biosciences, Inc. (NASDAQ:COGT) Expected to Earn Q2 2024 Earnings of ($0.66) Per ShareMay 11, 2024 | americanbankingnews.comCogent Biosciences, Inc. to Post Q2 2024 Earnings of ($0.63) Per Share, Lifesci Capital Forecasts (NASDAQ:COGT)May 10, 2024 | marketbeat.comQ2 2024 Earnings Estimate for Cogent Biosciences, Inc. Issued By Leerink Partnrs (NASDAQ:COGT)Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Equities researchers at Leerink Partnrs lowered their Q2 2024 earnings estimates for Cogent Biosciences in a report issued on Tuesday, May 7th. Leerink Partnrs analyst A. Berens now forecasts that the technology company will post earnings perMay 9, 2024 | americanbankingnews.comCogent Biosciences, Inc. (NASDAQ:COGT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 8, 2024 | markets.businessinsider.comBuy Rating on Cogent Biosciences Backed by Strong Financials and Promising Drug TrialsMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Clover Health Investments (CLOV), Cogent Biosciences (COGT) and Adaptive Biotechnologies (ADPT)May 8, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $18.00 price objective on shares of Cogent Biosciences in a research note on Wednesday.May 8, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Issues Quarterly Earnings Results, Misses Expectations By $0.11 EPSCogent Biosciences (NASDAQ:COGT - Get Free Report) released its quarterly earnings data on Tuesday. The technology company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.11).May 7, 2024 | markets.businessinsider.comBuy Recommendation for Cogent Biosciences Based on Promising Clinical Trials and Market PositionMay 7, 2024 | finance.yahoo.comCogent Biosciences Reports First Quarter 2024 Financial ResultsApril 29, 2024 | marketbeat.comShort Interest in Cogent Biosciences, Inc. (NASDAQ:COGT) Rises By 15.0%Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 12,470,000 shares, a growth of 15.0% from the March 31st total of 10,840,000 shares. Based on an average trading volume of 2,100,000 shares, the short-interest ratio is presently 5.9 days.April 29, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Shares Up 11.5%Cogent Biosciences (NASDAQ:COGT) Trading 11.5% HigherApril 25, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading Down 8.3%Cogent Biosciences (NASDAQ:COGT) Trading Down 8.3%April 22, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Shares Up 4%Cogent Biosciences (NASDAQ:COGT) Trading Up 4%April 18, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)April 14, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Rating of "Moderate Buy" from AnalystsCogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The avApril 10, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Price Down 7.3%Cogent Biosciences (NASDAQ:COGT) Trading Down 7.3%April 9, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Shares Up 6.3%Cogent Biosciences (NASDAQ:COGT) Shares Up 6.3%April 9, 2024 | globenewswire.comCogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 InhibitorApril 2, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading Down 8%Cogent Biosciences (NASDAQ:COGT) Shares Down 8%March 28, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Shares Acquired by SG Americas Securities LLCSG Americas Securities LLC grew its stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 203.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 317,409 shares of the technology company's stockMarch 27, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading 10.4% Higher Cogent Biosciences (NASDAQ:COGT) Shares Up 10.4%March 25, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading Down 5.2%Cogent Biosciences (NASDAQ:COGT) Stock Price Down 5.2%March 20, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five haveMarch 18, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Shares Gap Down to $7.05Cogent Biosciences (NASDAQ:COGT) Shares Gap Down to $7.05March 16, 2024 | finance.yahoo.comCOGT Apr 2024 7.500 callMarch 15, 2024 | marketbeat.comShort Interest in Cogent Biosciences, Inc. (NASDAQ:COGT) Expands By 45.4%Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) saw a large increase in short interest during the month of February. As of February 29th, there was short interest totalling 9,070,000 shares, an increase of 45.4% from the February 14th total of 6,240,000 shares. Based on an average daily volume of 2,600,000 shares, the short-interest ratio is presently 3.5 days.March 14, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Price Up 2.4%Cogent Biosciences (NASDAQ:COGT) Trading 2.4% HigherMarch 14, 2024 | insidermonkey.com5 Best Biotech Stocks To Buy Under $20March 12, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading Down 4%Cogent Biosciences (NASDAQ:COGT) Shares Down 4%March 4, 2024 | marketbeat.comKynam Capital Management LP Has $21.55 Million Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)Kynam Capital Management LP boosted its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 36.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,210,125 shares of the technologyMarch 2, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Shares Acquired by Fmr LLCFmr LLC grew its position in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 1,322.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,569,781 shares of the technology company's stock after purchasFebruary 29, 2024 | marketbeat.comLeerink Partnrs Equities Analysts Raise Earnings Estimates for Cogent Biosciences, Inc. (NASDAQ:COGT)Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Equities researchers at Leerink Partnrs increased their FY2024 earnings estimates for Cogent Biosciences in a note issued to investors on Monday, February 26th. Leerink Partnrs analyst A. Berens now anticipates that the technology company wilFebruary 28, 2024 | finance.yahoo.comCOGT Reports Full Year 2023 Financial Results and Business HighlightsFebruary 28, 2024 | marketbeat.comHC Wainwright Analysts Boost Earnings Estimates for Cogent Biosciences, Inc. (NASDAQ:COGT)Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Equities researchers at HC Wainwright lifted their Q1 2024 earnings per share (EPS) estimates for shares of Cogent Biosciences in a research report issued to clients and investors on Monday, February 26th. HC Wainwright analyst R. Burns now fFebruary 27, 2024 | msn.comBaird Downgrades Cogent Biosciences (COGT)February 27, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Issues Quarterly Earnings Results, Misses Estimates By $0.08 EPSCogent Biosciences (NASDAQ:COGT - Get Free Report) announced its quarterly earnings data on Monday. The technology company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.08).February 26, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Price Target Raised to $13.00Citigroup upped their target price on Cogent Biosciences from $11.00 to $13.00 and gave the company a "buy" rating in a report on Monday.February 26, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Shares Gap Down to $7.44Cogent Biosciences (NASDAQ:COGT) Shares Gap Down to $7.44February 26, 2024 | msn.comCogent Biosciences GAAP EPS of -$0.63February 26, 2024 | marketbeat.comCogent Biosciences' (COGT) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Cogent Biosciences in a research report on Monday. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking $16T Elon Musk Crypto Leak (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. COGT Media Mentions By Week COGT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COGT News Sentiment▼-0.050.42▲Average Medical News Sentiment COGT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COGT Articles This Week▼102▲COGT Articles Average Week Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CureVac News Wave Life Sciences News AnaptysBio News Nuvation Bio News Sage Therapeutics News GH Research News Calliditas Therapeutics AB (publ) News Nurix Therapeutics News Phibro Animal Health News Aurinia Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COGT) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingUrgent Nvidia WarningAltimetry[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsNext President (Not Trump. Not Biden.)The Freeport Society41 banks launch ‘crypto dollar’Stansberry ResearchMost important medical advance in 100 yearsThe Oxford ClubForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
